FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study

Authors :: Alberto Servetto
Antonio Santaniello
Fabiana Napolitano
Francesca Foschini
Roberta Marciano
Priscilla Cascetta
Anna Rita Amato
Maria Rosaria Augurio
Lucia Maresca
Pietro De Placido
Sabino De Placido
Luigi Formisano
Roberto Bianco
Servetto, Alberto
Santaniello, Antonio
Napolitano, Fabiana
Foschini, Francesca
Marciano, Roberta
Cascetta, Priscilla
Amato, Anna Rita
Augurio, Maria Rosaria
Maresca, Lucia
De Placido, Pietro
De Placido, Sabino
Formisano, Luigi
Bianco, Roberto
Source :: Future oncology (London, England). 18(21)
Publication Year :: 2022
Abstract: Aim: Comparison of first-line FOLFIRINOX (FFN) and nab-paclitaxel plus gemcitabine (NabGem) in patients with metastatic pancreatic ductal adenocarcinoma. Patients & methods: The authors analyzed data from 160 patients with metastatic pancreatic adenocarcinoma receiving first-line FFN (n=43) or NabGem (n=117). Results: FFN and NabGem were similar in median progression-free survival (24.43 vs 26.28weeks; hazard ratio [HR]: 0.88) and medial overall survival (47.43 vs 42.86weeks; HR: 0.90). Of the 43 patients receiving FFN, 26 (60.4%) were treated with second-line NabGem; 14/117 (12.0%) patients receiving NabGem received second-line FFN (p&nbsp

Tools